NCT00887107View on ClinicalTrials.gov

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2007

Conditions
Thyroid Cancer
Interventions
DRUG

Sorafenib (nexavar)

6 months therapy with Sorafenib 800 mg/day

Trial Locations (1)

2300 RC

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER

NCT00887107 - Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma | Biotech Hunter | Biotech Hunter